Last reviewed · How we verify
Tislelizumab + cisplatin + paclitaxel
Tislelizumab blocks PD-1 to restore anti-tumor immunity, while cisplatin and paclitaxel provide direct cytotoxic chemotherapy.
Tislelizumab blocks PD-1 to restore anti-tumor immunity, while cisplatin and paclitaxel provide direct cytotoxic chemotherapy. Used for Non-small cell lung cancer (NSCLC), Squamous cell carcinoma of the head and neck.
At a glance
| Generic name | Tislelizumab + cisplatin + paclitaxel |
|---|---|
| Sponsor | First Affiliated Hospital Xi'an Jiaotong University |
| Drug class | PD-1 inhibitor + chemotherapy combination |
| Target | PD-1 (tislelizumab); DNA (cisplatin); microtubule (paclitaxel) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
Tislelizumab is a humanized anti-PD-1 monoclonal antibody that releases the brakes on T-cell-mediated anti-tumor immunity by blocking the PD-1/PD-L1 checkpoint. Cisplatin is a platinum-based alkylating agent that cross-links DNA, while paclitaxel is a taxane that stabilizes microtubules and prevents cell division. The combination leverages immunotherapy with conventional chemotherapy for enhanced anti-tumor activity.
Approved indications
- Non-small cell lung cancer (NSCLC)
- Squamous cell carcinoma of the head and neck
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
- Nausea and vomiting
- Peripheral neuropathy
- Immune-related adverse events (pneumonitis, hepatitis)
Key clinical trials
- Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC) (PHASE3)
- A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer (PHASE2)
- A Phase II Clinical Study of LBL-024 Combination Therapy in Patients With Advanced Solid Tumour[Substudy 03(ESCC)] (PHASE2)
- Study of Tislelizumab Combined With Chemoradiotherapy and Surgery for Unresectable Esophageal Squamous Cell Carcinoma (PHASE2)
- Efficacy, Safety, and Pharmacodynamics of Tislelizumab Monotherapy and Multiple Tislelizumab-based Immunotherapy Combinations in Participants With Resectable Non-Small Cell Lung Cancer (PHASE2)
- Neoadjuvant Immunochemotherapy and Chemoradiotherapy Followed by Surgery for Advanced Esophageal Squamous Cell Carcinoma (PHASE2)
- Induction Chemotherapy Combined With Tislelizumab for Locally Advanced Squamous Cell Carcinoma of the External Auditory Canal (PHASE2)
- Lingual Nerve Disruption to Augment Neoadjuvant Chemoimmunotherapy in Locally Advanced Tongue Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: